Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials

Fig. 1

Changes in glucose metabolism markers from baseline to Week 12 (LOCF). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. placebo (ANCOVA with baseline value as covariate). HOMA-IR was calculated using the following formula: HOMA-IR = fasting serum insulin (µU/mL) × fasting plasma glucose (mmol/L)/22.5. HOMA-IR homeostatic model assessment of insulin resistance, HbA1c hemoglobin A1c, SD standard deviation, LS least squares, CI confidence interval, LOCF last observation carried forward, ANCOVA analysis of covariance

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840